BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3698052)

  • 1. Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.
    Green MR; Vosika G; Propert KJ; Ware JH; Comis R
    Cancer Treat Rep; 1986 Apr; 70(4):539-40. PubMed ID: 3698052
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
    Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
    Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
    Myers JW; Von Hoff DD; Clark GM; Coltman CA
    Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of advanced non-small cell lung cancer with bisantrene.
    Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
    Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
    Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
    Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
    Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
    Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
    [No Abstract]   [Full Text] [Related]  

  • 7. Bisantrene, an active drug in patients with advanced breast cancer.
    Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
    Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of bisantrene in non-small cell lung cancer.
    Miller TP; Ahmann FR; Mackel C; Greenberg BR; Alberts DS
    Invest New Drugs; 1985; 3(4):393-5. PubMed ID: 4086247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study.
    McGuire WP; Blough RR; Cobleigh MA; Johnson CM; Kukla LJ; Lad TE; Lanzotti VJ; Stiff PJ; Zawila P
    Cancer Treat Rep; 1983 Sep; 67(9):841-2. PubMed ID: 6883363
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
    Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of bisantrene in patients with metastatic melanoma.
    Mackel C; Meyskens FL; Alberts DS
    Cancer Treat Rep; 1986 Aug; 70(8):1037-8. PubMed ID: 3731151
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
    Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
    Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
    Conley BA; Hornedo J; Abrams J; Eisenberger M; Hiponia D; Aisner J; Van Echo DA
    Cancer Treat Rep; 1987 Sep; 71(9):861-2. PubMed ID: 3040246
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II trial of bisantrene in advanced colorectal carcinoma.
    Ahmed T; Kemeny NE; Michaelson RA; Harper HD
    Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
    Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
    Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study on DON in patients with previously treated advanced lung cancer.
    Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
    Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of bisantrene in advanced colorectal cancer: a cancer and leukemia group B study.
    Perry MC; Forastiere AA; Richards F; Weiss RB; Anbar D
    Cancer Treat Rep; 1982 Nov; 66(11):1997-8. PubMed ID: 7139643
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of acivicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Greco A; Prestridge K; Johnson R
    Cancer Treat Rep; 1986 Aug; 70(8):1031-2. PubMed ID: 3524833
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer and leukemia group B phase II non-small cell lung carcinoma trial: aziridinylbenzoquinone (AZQ).
    Carey RW; Comis RL; Anbar D; Kennedy BJ; Capizzi RL; Shulman P; Booth BW; Green M; Raich PC
    Cancer Treat Rep; 1983 Jan; 67(1):95-6. PubMed ID: 6616498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.